-
公开(公告)号：JP2009108086A
公开(公告)日：2009-05-21
申请号：JP2008294819
申请日：2008-11-18
Applicant: Ucb Pharma Sa , ユセベ ファルマ ソシエテ アノニム
Inventor： POPPLEWELL ANDREW GEORGE , TICKLE SIMON PETER , ZINKEWICH-PEOTTI KAREN , MORRISON ROBERT KENDALL
IPC: C07K16/28 , C12N15/09 , A61K39/395 , A61K47/48 , A61P9/00 , A61P17/00 , A61P17/06 , A61P19/02 , A61P29/00 , A61P35/00 , A61P35/04 , A61P37/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/13 , C12P21/02 , C12P21/08
CPC classification number: C07K16/2863 , A61K2039/505 , C07K2317/24 , C07K2317/55 , C07K2317/565
Abstract: PROBLEM TO BE SOLVED: To provide antibody molecules containing at least one CDR obtained from a mouse monoclonal antibody having specificity for human KDR. SOLUTION: A CDR grafted antibody in which at least one of the CDRs is a hybrid CDR is disclosed. Also DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases, in which VEGF and/or KDR are implicated, are disclosed. COPYRIGHT: (C)2009,JPO&INPIT
Abstract translation: 待解决的问题：提供含有至少一种CDR的抗体分子，其获自具有对人KDR特异性的小鼠单克隆抗体。 解决方案：公开了其中至少一个CDR是杂交CDR的CDR移植抗体。 还公开了编码抗体分子链，载体，转化的宿主细胞的DNA序列和抗体分子在其中涉及VEGF和/或KDR的疾病的治疗中的用途。 版权所有（C）2009，JPO＆INPIT
-
公开(公告)号：JP2010022372A
公开(公告)日：2010-02-04
申请号：JP2009205660
申请日：2009-09-07
Applicant: Ucb Pharma Sa , ユセベ ファルマ ソシエテ アノニム
IPC: C07K16/18 , C12N15/09 , A61K38/16 , A61K39/395 , A61P35/00 , C07K16/28 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/13 , C12N15/63 , C12P21/00 , C12P21/08 , G01N33/53
CPC classification number: C07K16/464 , A61K2039/505 , A61K2039/507 , C07K16/2803 , C07K16/2851 , C07K16/3061 , C07K2317/20 , C07K2317/24 , C07K2317/40 , C07K2317/41 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
Abstract: PROBLEM TO BE SOLVED: To provide antibody molecules for treating NHL (non-Hodgkin lymphoma), repeatedly usable and easily and efficiently producible. SOLUTION: There is provided an antibody containing at least one CDR (Complementarity Determining Region) derived from a mouse monoclonal antibody having specificity for CD22. Also provided is a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further provided are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and use of the antibody molecules in the treatment of diseases mediated by cells expressing CD22. COPYRIGHT: (C)2010,JPO&INPIT
Abstract translation: 要解决的问题：提供用于治疗NHL（非霍奇金淋巴瘤）的抗体分子，可重复使用且容易且高效地生产。 解决方案：提供了含有至少一种衍生自对CD22具有特异性的小鼠单克隆抗体的CDR（互补决定区）的抗体。 还提供了CDR移植抗体，其中至少一个CDR是修饰的CDR。 还提供了编码抗体分子链，载体，转化的宿主细胞的链DNA序列和抗体分子在治疗由表达CD22的细胞介导的疾病中的用途。 版权所有（C）2010，JPO＆INPIT
-
公开(公告)号：JP2013230158A
公开(公告)日：2013-11-14
申请号：JP2013140245
申请日：2013-07-04
Applicant: Ucb Pharma Sa , ユセベ ファルマ ソシエテ アノニム
IPC: C07K16/18 , C12N15/09 , A61K31/7088 , A61K38/16 , A61K39/395 , A61K45/00 , A61K48/00 , A61P35/00 , C07K16/28 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/13 , C12N15/63 , C12P21/00 , C12P21/08
CPC classification number: C07K16/464 , A61K2039/505 , A61K2039/507 , C07K16/2803 , C07K16/2851 , C07K16/3061 , C07K2317/20 , C07K2317/24 , C07K2317/40 , C07K2317/41 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
Abstract: PROBLEM TO BE SOLVED: To provide antibody molecules for treating NHL, capable of being repeatedly used and easily and efficiently produced.SOLUTION: An antibody containing at least one CDR obtained from a mouse monoclonal antibody having specificity to CD22 is disclosed. A CDR transplanted antibody, wherein at least one CDR is a modified CDR, is also disclosed. Furthermore, a DNA sequence encoding chains of antibody molecules, a vector, transformed host cells and use of the antibody molecules in the treatment of diseases mediated with CD22 expressing cells are disclosed.
Abstract translation: 要解决的问题：提供用于治疗NHL的抗体分子，能够重复使用并且容易且有效地产生。解决方案：公开了含有至少一种CDR的抗体，其具有对CD22特异性的小鼠单克隆抗体。 还公开了CDR移植抗体，其中至少一个CDR是经修饰的CDR。 此外，公开了编码抗体分子链，载体，转化的宿主细胞的DNA序列和抗体分子在用CD22表达细胞介导的疾病的治疗中的用途。
-
公开(公告)号：PT1814915E
公开(公告)日：2014-03-25
申请号：PT05803526
申请日：2005-11-16
Applicant: UCB PHARMA SA
Inventor： POPPLEWELL ANDREW GEORGE , TICKLE SIMON PETER , ADAMS RALPH , RAPECKI STEPHEN EDWARD
-
公开(公告)号：SG161744A1
公开(公告)日：2010-06-29
申请号：SG2006084065
申请日：2003-05-02
Applicant: UCB PHARMA SA
IPC: C07K16/18 , A61K38/16 , A61K39/395 , A61P35/00 , C07K16/28 , C12N15/13 , C12N15/63 , C12P21/00 , A61K31/7088 , C12N5/10 , C12N15/85
Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22.
-
Patent Agency Ranking
公开(公告)号：DE60331910D1
公开(公告)日：2010-05-12
申请号：DE60331910
申请日：2003-05-02
Applicant: UCB PHARMA SA
IPC: C07K16/18 , C07K16/28 , A61K31/7088 , A61K38/16 , A61K39/395 , A61P35/00 , C12N5/10 , C12N15/13 , C12N15/63 , C12N15/85 , C12P21/00
Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22.
-
公开(公告)号：AU2002334135B2
公开(公告)日：2009-01-08
申请号：AU2002334135
申请日：2002-10-10
Applicant: UCB PHARMA SA
Inventor： ZINKEWICH-PEOTTI KAREN , POPPLEWELL ANDREW GEORGE , TICKLE SIMON PETER , MORRISON ROBERT KENDALL
IPC: C12N15/09 , A61K39/395 , A61K47/48 , A61P17/00 , A61P17/06 , A61P19/02 , A61P29/00 , A61P35/00 , A61P35/04 , A61P37/00 , C07K16/28 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/13 , C12P21/02 , C12P21/08
Abstract: There are disclosed antibody molecules containing at least on CDR derived from a mouse monoclonal antibody having specificity for human KDR. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases in which VEGF and/or KDR are implicated.
-
公开(公告)号：AU2003223007C1
公开(公告)日：2019-08-08
申请号：AU2003223007
申请日：2003-05-02
Applicant: UCB PHARMA SA
Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22.
-
-
公开(公告)号：CY1110134T1
公开(公告)日：2015-01-14
申请号：CY101100492
申请日：2010-06-03
Applicant: UCB PHARMA SA
IPC: C07K16/18 , C07K16/28 , A61K31/7088 , A61K38/16 , A61K39/395 , A61P35/00 , C12N5/10 , C12N15/13 , C12N15/63 , C12N15/85 , C12P21/00
Abstract: Περιγράφονταιμόριααντισώματοςταοποίαπεριέχουντουλάχιστονμια CDR ηοποίαπροέρχεταιαπόέναμονοκλωνικόαντίσωμαποντικού, τοοποίοέχειειδικότηταγιατο CD22 τουανθρώπου. Περιγράφεταιεπίσηςένα CDR μεταμοσχευμένοαντίσωμαστοοποίοτουλάχιστονμιααπότις CDRs είναιμιατροποποιημένη CDR. Περιγράφονταιεπίσηςαλληλουχίες DNA, οιοποίεςκωδικοποιούντιςαλυσίδεςτωνμορίωντουαντισώματος, οιφορείς, ταμετασχηματισμένακύτταραξενιστέςκαιη χρήσηαυτώντωνμορίωντουαντισώματοςστηνθεραπείατωνασθενειών, οιοποίεςμεσολαβούνταιαπότακύτταρα, ταοποίαεκφράζουντο CD22.
-
-
-
-
-
-
-
-
-
Search Results
43
records
(took 0.026 seconds)
